IL‐1 inhibition reduced cardiovascular events in the Canakinumab Antiinflammatory Thrombosis Outcome Study trial, and IL‐6 inhibition has been found to have beneficial effects on markers of atherosclerosis such as carotid intima‐media thickness (47) and to reduce cardiovascular events in RA (52). Here, IL6 is linked to rheumatoid arthritis.